Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Lentivirally and alpharetrovirally engineered CD19 NK CAR-cells in ALL

Tobias Bexte • 31 Aug 2020
EBMT 2020
Acute Lymphoblastic Leukemia Leukemia CAR-T NK-Cell Therapy

Tobias Bexte, cand.med., University Hospital Frankfurt, Goethe University, Frankfurt, Germany, discusses his abstract on lentivirally and alpharetrovirally engineered CD19 specific chimeric antigen receptor (CAR) natural killer (NK) cells and their use in acute lymphoblastic leukemia (ALL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Tobias Bexte

3:33
Targeting tumor cells through non-viral Sleeping Beauty transposon engineered CD19-CAR-NK cells
Tobias Bexte • 25 Apr 2023
1:19
Gene editing of NKG2A to enhance NK cell cytotoxicity against multiple myeloma cells
Tobias Bexte • 16 Mar 2022
0:48
Advantages of primary NK cells for the treatment of patients with hematological malignancies
Tobias Bexte • 16 Mar 2022
0:59
Next steps for gene-edited NK cells in the treatment of hematological malignancies
Tobias Bexte • 16 Mar 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals